Fig. 3: Expression profiling of selected JQ1-sensitive and JQ1-resistant GBM cell lines following JQ1 treatment.
From: BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells
a, b Top 100 differentially expressed genes in JQ1-sensitive and JQ1-resistant GBM cell lines upon 6 h JQ1 inhibition. Gene names (rows) can be found in Tables S3–S6. c Gene set overlap showing direct suppression of genes regulating cell cycle and cytoskeleton, and upregulation of cell death mechanisms in JQ1-sensitive cells. d Gene set overlap following JQ1 inhibition of JQ1-resistant cells showing suppression of genes regulating intracellular signal transduction, necrosis and response to DNA damage, and upregulation of genes regulating cell proliferation. e MYCN significantly correlates (Spearman correlation) with sensitivity to JQ1, where high MYCN expression confers sensitivity in GBM cell lines. On the other hand, MYC expression showed no correlation (Spearman correlation) with the sensitivity to JQ1 inhibition. f 6 h JQ1 inhibition (500 nM) failed to significantly decrease expression of MYC, with one resistant GBM cell line upregulating its expression. g Following 6 h JQ1 treatment (500 nM), the sensitive cell lines dramatically decreased MYCN expression, while the resistant cells showed absence of MYCN in both treated and untreated conditions.
